The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SABS | -10.28% | N/A | N/A | -96% |
| S&P | +15.98% | +86.41% | +13.26% | +76% |
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. It is engaged in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. SAB Biotherapeutics was founded by Eddie J. Sullivan and Christine E. Hamilton and is headquartered in Sioux Falls, SD.
No news articles found for Sab Biotherapeutics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$765.47K | 20.8% |
| Gross Margin | -585.03% | -375.4% |
| Market Cap | $20.93M | -16.0% |
| Market Cap / Employee | $332.16K | 0.0% |
| Employees | 63 | 10.5% |
| Net Income | $5.34M | 151.6% |
| EBITDA | -$11,913.50K | -15.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $29.42M | 220.8% |
| Accounts Receivable | $0.00K | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $5.20M | 30.1% |
| Short Term Debt | $988.32K | 88.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -18.01% | 92.9% |
| Return On Invested Capital | -46.11% | -17.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$13,050.02K | -103.4% |
| Operating Free Cash Flow | -$13,050.02K | -106.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.95 | 0.49 | 0.76 | 1.55 | 187.67% |
| Price to Sales | 26.63 | 33.44 | 142.22 | 1364.50 | 8156.49% |
| Price to Tangible Book Value | 0.95 | 0.49 | 0.76 | 1.55 | 187.67% |
| Enterprise Value to EBITDA | -2.07 | -0.66 | -1.91 | -4.35 | -5208.07% |
| Return on Equity | -81.9% | -92.4% | -127.5% | -21.2% | -87.89% |
| Total Debt | $4.67M | $6.78M | $6.42M | $6.19M | 36.88% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
